FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D C | 20540 |
|--------------|------|-------|
| wasiiiigton, | D.C. | 20049 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average b | ourden | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | 01 0 | OCCI | 1011 30(11) 0 | of the | IIIVCStilic | 11 001 | прапу Асс | 01 10-10 | | | | | | | |
|--|--|--|---|---------|--|---|---------------------|---|--|---|---|------------------|---|--|--------------------------------------|---|---------------------------------------|--|--|
| Name and Address of Reporting Person* Herzich Paul | | | | | | 2. Issuer Name and Ticker or Trading Symbol Solid Biosciences Inc. [SLDB] | | | | | | | | | of Reportin cable) or | g Pers | son(s) to Iss | | |
| (Last) | , | irst) IENCES INC. | (Middle) | | | | of Earliest 2024 | Trans | action (M | onth/l | Day/Year) | | A below | , | nolog | Other (specify below) | | | |
| 500 RUTHERFORD AVENUE, THIRD FLOOR | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) CHARLESTOWN MA 02129 | | | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | $ _{\Box}$ | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Tab | le I - Nor | ı-Deriv | ative | Se | curities | s Ac | quired, | Dis | posed c | of, or Be | neficial | ly Owne | t | | | | |
| 1. Title of Security (Instr. 3) 2. Transc Date (Month/D | | | | | 2A. Deemed Execution Date oay/Year) if any (Month/Day/Yea | | | e, Transaction Disposed Code (Instr. 5) | | rities Acquired (A) ed Of (D) (Instr. 3, 4 | | Benefic Owned | es Formially (D) (Following (I) (I | | m: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount | nt (A) or Pi | | Reporte Transac (Instr. 3 | ction(s) | | | (Instr. 4) | | |
| Common Stock | | | | | | | | | | | | | | 6,022(1) | | | D | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution I if any (Month/Day | Date, 7 | 4. Transaction Code (Instr. 8) | | n of E | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4) | e s illy | Ownershi Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisal | | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Employee Stock Option (Right to Buy) | \$7.85 | 02/13/2024 | | | A | | 57,500 | | (2) | |)2/13/2034 | Common Stock | 57,500 | \$0.00 | 57,50 | 0 | D | | |
| Restricted Stock | (3) | 02/13/2024 | | | A | | 28,750 | | (4) | | (4) | Common | 28,750 | \$0.00 | 28,75 | 0 | D | | |

Explanation of Responses:

- 1. Includes 1,752 shares of the issuer's common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2023.
- 2. This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
- 3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
- 4. The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

/s/ David Tyronne Howton as 02/16/2024 attorney-in-fact for Paul **Herzich**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.